Drugs / GSK3128349
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02829307 | Aug 2016 → Jan 2017 | drug-induced mental disorder | GlaxoSmithKline | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GSK3128349 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02829307 ↗ |
| Modality | Protein / enzyme biologic | “GSK3128349 is a small protein molecule (biopharmaceutical)” NCT02829307 ↗ |
| Route | Intravenous | “single intravenous infusion” NCT02829307 ↗ |